Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 1
2005 1
2006 3
2007 5
2008 4
2009 3
2010 8
2011 12
2012 21
2013 13
2014 17
2015 17
2016 31
2017 37
2018 41
2019 48
2020 42
2021 41
2022 29
2023 41
2024 19

Text availability

Article attribute

Article type

Publication date

Search Results

372 results

Results by year

Filters applied: . Clear all
Page 1
The Genomic, Transcriptomic, and Immunologic Landscape of HRAS Mutations in Solid Tumors.
Kareff SA, Trabolsi A, Krause HB, Samec T, Elliott A, Rodriguez E, Olazagasti C, Watson DC, Bustos MA, Hoon DSB, Graff SL, Antonarakis ES, Goel S, Sledge G, Lopes G. Kareff SA, et al. Among authors: antonarakis es. Cancers (Basel). 2024 Apr 19;16(8):1572. doi: 10.3390/cancers16081572. Cancers (Basel). 2024. PMID: 38672653 Free PMC article.
Correction: A multidisciplinary approach to address unmet needs in the management of patients with non-metastatic castration-resistant prostate cancer.
Shore ND, Antonarakis ES, Ross AE, Marshall CH, Stratton KL, Ayanambakkam A, Cookson MS, McKay RR, Bryce AH, Kaymakcalan MD. Shore ND, et al. Among authors: antonarakis es. Prostate Cancer Prostatic Dis. 2024 Apr 20. doi: 10.1038/s41391-024-00835-x. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 38643308 No abstract available.
Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancers.
Muquith M, Espinoza M, Elliott A, Xiu J, Seeber A, El-Deiry W, Antonarakis ES, Graff SL, Hall MJ, Borghaei H, Hoon DSB, Liu SV, Ma PC, McKay RR, Wise-Draper T, Marshall J, Sledge GW, Spetzler D, Zhu H, Hsiehchen D. Muquith M, et al. Among authors: antonarakis es. Nat Cancer. 2024 Mar 25. doi: 10.1038/s43018-024-00752-x. Online ahead of print. Nat Cancer. 2024. PMID: 38528112
A multidisciplinary approach to address unmet needs in the management of patients with non-metastatic castration-resistant prostate cancer.
Shore ND, Antonarakis ES, Ross AE, Marshall CH, Stratton KL, Ayanambakkam A, Cookson MS, McKay RR, Bryce AH, Kaymakcalan MD. Shore ND, et al. Among authors: antonarakis es. Prostate Cancer Prostatic Dis. 2024 Mar 2. doi: 10.1038/s41391-024-00803-5. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 38431761 Review.
Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes.
Zorko NA, Makovec A, Elliott A, Kellen S, Lozada JR, Arafa AT, Felices M, Shackelford M, Barata P, Zakharia Y, Narayan V, Stein MN, Zarrabi KK, Patniak A, Bilen MA, Radovich M, Sledge G, El-Deiry WS, Heath EI, Hoon DSB, Nabhan C, Miller JS, Hwang JH, Antonarakis ES. Zorko NA, et al. Among authors: antonarakis es. Prostate Cancer Prostatic Dis. 2024 Feb 28. doi: 10.1038/s41391-024-00797-0. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 38418892
372 results